Extreme Transformation Of Simon Lafontant (Credit-goliath_gg/Instagram)
We often see celebrities go through weight loss transformations, with side-by-side comparisons of the before and after weight loss. But people often do not feel inspired or drawn to their stories as we all know that they have access to great personal trainers, high-end food products as well as better access to healthcare. But one story that was highlighted by Men’s Health in their ‘First Steps’ series can inspire many with the story of Simon Lafontant, who lost 150 pounds and went on to become a body builder.
Simon Lafontant, a 32-year-old from Calgary, had to deal with some serious health problems for a long time. These included low testosterone and Crohn's disease, which made his life difficult. But Simon decided he wanted to make a change. He got medical help for his low testosterone and then set a big goal for himself: to compete in a bodybuilding competition. He used social media to keep himself on track, and he ended up losing over 150 pounds and even winning the competition! His story is about how he went from struggling with his health to becoming a bodybuilding champion.
Simon talks about how he used to have bad habits and wasn't living a healthy lifestyle. This led to him feeling down, gaining weight, and losing motivation. Things got really serious in 2020 when his Crohn's disease caused him to be in the hospital for seven whole months. According to Mayo Clinic Crohn’s disease is a type of inflammatory bowel disease that is inflammation in your digestive tract which can be very painful and can cause people to need long term remission and time to heal the inflammation. Simon spoke about how he realized his poor lifestyle choices and being obese had made his symptoms worse!
While you may not wish to become a bodybuilder, there are many other aspects you can take away from the Simon’s story! Another trip to the doctors revealed that he had very low testosterone levels, which explained his lack of energy. This was a major turning point for him, as he finally understood some of the reasons behind his struggles.
One thing that made a huge difference in Simon’s weight loss journey was getting the TRT treatment for his low testosterone which had an almost immediate effect on him. He felt good, started enjoying things again, like going outside and working out. He also remembered how much he loved powerlifting and Strongman competitions, so this helped him get on to his path to bodybuilding and weight training!
Low testosterone affects both men and women, but in different ways. In women, it can cause low sex drive, tiredness, muscle weakness, trouble getting pregnant, irregular periods, vaginal dryness, mood changes like depression or anxiety, hair thinning, dry skin, and sleep problems. In men, low testosterone can lead to reduced sex drive, erectile dysfunction, hair loss, smaller testicles, hot flashes, and infertility. Other symptoms in men include feeling down, trouble concentrating or remembering things, and increased body fat. If you're experiencing any of these symptoms, it's a good idea to talk to a doctor.
Credit: Instagram
Amanda Peet, the Hollywood actress known for roles in Something’s Gotta Give, The Whole Nine Yards, and Jack & Jill, recently opened up about her breast cancer diagnosis and how informing her kids about her health became the toughest part for her.
In a New Yorker essay published March 21, the 54-year-old actress announced how a routine scan in August 2025 showed an unusual ultrasound result. Later, a biopsy detected a tumor that “appeared” small.
The Dirty John star found to be in stage 1 of lobular cancer that is “hormone-receptor-positive” and “HER2-negative,” making her “happier than the pre-diagnosis” stage.
It is because Hormone-receptor-positive and HER2-negative cancer is less aggressive and often easier to treat than more aggressive forms of breast cancer.
However, informing her children, Frances, 19, Molly, 15, and Henry, 11, about the cancer was the toughest part for her, and she had to be in the right mindset before sharing the news with them.
“They've been great,” Peet told E! News.
“I definitely had to get myself together before including them. The hard part was realizing that nothing is certain and there was going to be no perfect time to tell them,” she added.
Peet stated that between her diagnosis, she had also been navigating a series of family health crises — with both of her parents' final months in hospice care.
The Your Friends & Neighbors actress, in her essay, also noted that she would “only need a lumpectomy and radiation,” not a double mastectomy.
Also read: Jane Fallon Diagnosed With Breast Cancer, This Is How She Caught It Early
Invasive Lobular Carcinoma (ILC) the second most common form of breast cancer, representing 5 to 15 percent of breast cancer cases.
Rather than a distinct lump, it can appear as a thickening or "fullness" rather than a tumor.
It is often difficult to detect on mammograms, thus MRI or ultrasound are more effective for detection
It is usually hormone receptor-positive.
HR+ and HER2− breast cancer is the most common subtype and is seen among 60–75 per cent of cases.
It is not two different cancers, but rather specific, defining characteristics of the same cancer type (breast cancer). It grows:
According to the Centers for Disease Control and Prevention (CDC), breast cancer screening is a proactive checkup used to find cancer before any physical signs or symptoms appear. While screening doesn’t prevent cancer, its goal is early detection, making the disease much easier to treat.
Since every person’s body and history are different, you and your doctor should engage in informed and shared decision-making. This means discussing the pros and cons to decide together if, and when, screening is right for you.
The US Preventive Services Task Force (a group of national medical experts) provides guidelines based on the latest research:
Average Risk
Women aged 40 to 74 should generally get a mammogram every two years.
High Risk
If you have a family history or other risk factors, your doctor may recommend a different schedule or additional tests.
Credit: iStock
GLP-1 receptor agonists are a modern class of medicines that have changed the treatment of type 2 diabetes and obesity. In simple terms, they help the body respond to food more smartly. After eating, the intestine naturally sends signals that help regulate sugar and appetite levels.
GLP-1 RA medicines imitate this signal. As a result, blood sugar rises less after meals, appetite becomes more controlled, and many people feel full with smaller amounts of food. This is why these medicines are used not only for diabetes, but also for weight reduction in selected people.
These medicines are important because their benefits can go beyond sugar control alone. Studies and current diabetes guidelines show that some GLP-1 RAs can reduce body weight, improve long-term sugar levels, and lower the risk of major heart-related problems in people who have type 2 diabetes and high cardiovascular risk.
Recent guidance also supports their use in some people with chronic kidney disease when cardiovascular risk reduction is an important goal. This does not mean every drug in the group is identical, but it means the class has become medically important for more than just lowering sugar.
For the general public, one important point is that these are not “miracle injections.”
They work best when combined with better food choices, regular walking or exercise, good sleep, and medical follow-up. They are usually started slowly because the commonest side effects are stomach-related, such as nausea, vomiting, constipation, loose motions, or a feeling of fullness.
Not everyone is suitable for them, and the decision depends on a person’s diabetes status, weight, heart or kidney disease, other medicines, and cost. Used properly, GLP-1 RAs are powerful tools that can improve health, but they should always be taken under medical supervision.
So Indian Medical Association (IMA) is planning to seek a mandate restricting prescriptions of GLP-1 drugs to certified endocrinologists/diabetologists or MD general medicine practitioners to curb indiscriminate use and safeguard patient safety as access expands, many media report in August last year about rampant misuse of GLP1 weight loss drugs by cosmetologists, physiotherapists, dermatologists, general MBBS clinicians, and even ayurveda, and other non-modern medicine practitioners.
Many MBBS, physiotherapists, and non-modern medicine practitioners are prescribing GLP1 drugs to people who neither have diabetes nor any comorbidity or acute obesity, but purely for cosmetic reasons to lose some weight that can be otherwise easily done with some lifestyle changes like exercise and diet.
It is a duty of the government to take care of it because there is a lot of misuse and misprescription that needs to be curbed immediately, because these medicines also have side effects.
We will write to the government to take necessary action to stop the misuse of the drug. We will discuss it in our meeting in the first week of April 2026.
Credit: iStock
One in four or 25 percent of adults with type-2 diabetes in India also suffer from liver fibrosis, according to an alarming study published in The Lancet Regional Health Southeast Asia journal today.
With data from more than 9,000 patients across the country, it is the largest ever real-world survey of liver fibrosis in type 2 diabetes from any low- or middle-income country.
While fatty liver disease has been touted as the most common liver condition among diabetes patients, the new study established liver fibrosis as the real danger among people with high blood sugar.
“Type 2 diabetes is closely linked to fatty liver disease (also known as MASLD). But how common is liver Fibrosis — the real danger — in Indian diabetics? Our answer: 1 in 4 has clinically significant liver fibrosis. One in 20 already has probable cirrhosis. Most had no symptoms. We propose liver fibrosis as the ‘4th major complication’ of diabetes,” said Ashish Kumar, from Ganga Ram Postgraduate Institute of Medical Education and Research (GRIPMER), from Sir Ganga Ram Hospital, in a post on social media platform X.
What Did The Study Find?
Fatty liver is typically the first and reversible stage of liver disease, where excess fat builds up in liver cells. Left untreated, it progresses to liver fibrosis, which is the excessive accumulation of scar tissue (collagen) in the liver resulting from chronic inflammation. The condition then progresses to the third and late stage, irreversible scarring (fibrosis) of the liver. The final stage is liver cancer.
The DiaFib-Liver Study included a total of 9,202 adults with type-2 diabetes patients who underwent FibroScan (VCTE) to assess liver fibrosis in routine diabetes care.
Of these:
The study suggested the urgent need to integrate fibrosis screening into national diabetes programs.
“One in four adults with type 2 diabetes in India has clinically significant liver fibrosis and one in twenty already has probable cirrhosis, establishing advanced liver disease as a 'fourth major complication' of diabetes,” said the researchers.
“The DiaFibLiver Study calls for: Fibrosis — not steatosis — as the screening target. FibroScan integration into routine diabetes care. Moving beyond ultrasound-based referral,” Jha said.
“We hope this data from India adds to the global conversation on diabetes and liver disease,” he added.
Also read: The Silent Rise of Fatty Liver Disease: How India-Specific Guidelines Can Help
The findings highlight the urgent need to:
Certain lifestyle choices can accelerate liver damage, such as:
Overeating processed or fried foods
High sugar intake (soft drinks, sweets, desserts)
Physical inactivity or prolonged sitting
Ignoring health issues like diabetes or hypertension
Crash dieting or taking unprescribed supplements.
Early screening and detection are key to prevent irreversible stages. Yet liver disease can be prevented with lifestyle changes such as:
© 2024 Bennett, Coleman & Company Limited